Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus
placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the
progression of motor disability in patients with early PD in order to assess its potential
"disease-modifying" effect.